Dextromethorphan

Introduction Overview

Generic Name

dextromethorphan

Brand Name

Babee Cof, Benylin DM Pediatric, Buckleys Mixture, Creomulsion, Creo-Terpin, DayQuil Cough, Delsym, Delsym 12 Hour Cough Relief, Elixsure Cough, Robafen Cough Liquidgels, Robitussin CoughGels, Scot-Tussin Diabetic, Silphen DM, St. Joseph Cough Suppressant, Sucrets DM Cough, Theraflu Thin Strips Cough, Triaminic Long Acting Cough

Dosage Form

Available as oral liquids, lozenges, disintegrating strips, capsules, and syrups

Drug Class

Antitussives

Pharmacokinetics

Absorption: Dextromethorphan is well absorbed from the gastrointestinal tract following oral administration. The peak plasma concentrations are typically achieved within 2 to 2.5 hours. Its absorption can be influenced by the formulation used, with extended-release formulations showing prolonged absorption phases to sustain therapeutic levels. Food intake generally does not significantly affect the bioavailability of dextromethorphan, although co-administration with certain substances such as grapefruit juice may alter metabolism.

Distribution: Dextromethorphan undergoes extensive distribution into body tissues. It is lipophilic, which allows it to cross the blood-brain barrier efficiently, exerting its central nervous system effects. The volume of distribution is moderate to large, reflecting its widespread distribution. Plasma protein binding is relatively low to moderate, facilitating availability to the target receptors in the CNS.

Metabolism: Dextromethorphan is primarily metabolized in the liver via the cytochrome P450 2D6 (CYP2D6) enzymatic pathway. The main metabolic pathways include O-demethylation to dextrorphan and N-demethylation to 3-methoxymorphinan, both of which have differing pharmacodynamic profiles. Genetic polymorphisms in CYP2D6 can result in variable metabolism rates, ranging from poor to ultra-rapid metabolizers, which clinically affects efficacy and risk of adverse effects. Other enzymes, including CYP3A4, can also contribute to minor metabolic pathways.

Elimination: The elimination half-life of dextromethorphan varies depending on metabolizer status but averages approximately 3 to 6 hours in normal CYP2D6 metabolizers. It is primarily excreted in the urine, mainly as metabolites, with less than 10% excreted unchanged. Renal impairment may affect clearance but does not typically necessitate dose adjustments. The elimination profile supports dosing multiple times per day or via sustained-release formulations to maintain therapeutic effects.

Dosage Forms

Available Dosage Forms: Dextromethorphan is available in several oral formulations including syrups, liquids, lozenges, disintegrating strips, capsules, and extended-release formulations. Specific preparations include immediate-release syrups and liquids, extended-release suspension (e.g., Delsym 12 Hour Cough Relief), cough capsules (liquidgels), and lozenges or thin strips designed for gradual dissolution in the oral cavity.

Dosages for Adults and Adolescents: Typical dosing for adults and children above 12 years involves 10-20 mg every 4 hours as needed, or 30 mg every 6 to 8 hours, not exceeding 120 mg per day. Extended-release formulations are generally dosed at 60 mg every 12 hours. For adolescents aged 4 years and above, dosing must be conservative and under supervision, as FDA recommends not administering to children younger than 4 years.

Specific Patient Populations: In pediatric patients, dosing must be adjusted carefully according to age and weight, with a strong recommendation against use in children under 4 years due to risk of serious adverse effects. For patients with hepatic impairment, caution is advised due to metabolism predominantly occurring in the liver, though no formal dose adjustments are universally mandated. Patients with renal impairment typically do not require dosing changes, although clinical monitoring is prudent. Special populations such as pregnant or breastfeeding women should only use dextromethorphan with medical supervision due to limited data on safety.

Additional Notes: The measurement of liquid doses should always be performed using appropriate dosing devices rather than household spoons to ensure accuracy and safety in administration.

Mechanism Of Action

Dextromethorphan exerts its antitussive effects primarily through central nervous system action by modulating the cough reflex pathway. Its principal molecular mechanism involves noncompetitive antagonism of the N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptor involved in excitatory neurotransmission. By blocking NMDA receptors, dextromethorphan reduces the excitability of neurons in the brainstem cough center, leading to suppression of cough reflex.

Additionally, dextromethorphan interacts with sigma-1 receptors, which are chaperone proteins that modulate neurotransmitter systems and neuronal excitability. Activation of these receptors by dextromethorphan contributes to its neuromodulatory and analgesic properties, potentially modulating sensory input related to cough stimuli. This receptor profile differentiates dextromethorphan from traditional opioids, reducing abuse potential and side effects.

At the cellular level, dextromethorphan affects voltage-gated calcium channels and may reduce neurotransmitter release implicated in cough hypersensitivity. Its metabolite, dextrorphan, shares similar NMDA antagonist activity and contributes to the pharmacodynamic effects. Unlike opioid antitussives such as codeine, dextromethorphan does not significantly bind to opioid receptors, minimizing sedation and respiratory depression risks.

Clinically, this mechanism underpins its effectiveness in suppressing non-productive cough without substantial central respiratory suppression. Research has also explored its potential neuroprotective and anti-inflammatory properties via NMDA receptor modulation, with ongoing investigations into broader applications beyond cough suppression.

Pharmacological Actions

Central cough reflex suppression via NMDA receptor antagonism.
Modulation of sigma-1 receptors affecting neuronal excitability.
Non-opioid antitussive effects reducing cough without significant sedation.
Reduction of neurotransmitter release involved in cough hypersensitivity.
Metabolite dextrorphan contributes to NMDA receptor antagonism.
Minimal activity at opioid receptors, reducing abuse and respiratory depression risk.
Potential neuromodulatory and analgesic properties through sigma receptor activity.
Off-label investigation for neuroprotective effects.
Influences central nervous system pathways responsible for cough generation.
Acts selectively on the brainstem cough center to dampen reflex sensitivity.
Does not impair mucociliary clearance or respiratory drive significantly.
Blocks glutamate excitatory neurotransmission implicated in cough reflex.

Therapeutic Or Clinical Uses

Symptomatic relief of nonproductive cough.
Treatment of cough associated with upper respiratory infections.
Component in combination cold and cough over-the-counter products.
Used to reduce cough severity in common cold and bronchitis.
Alternative to opioid antitussives with lower abuse potential.
Temporary relief of cough not caused by asthma or emphysema.
Adjunctive therapy to improve patient comfort in cough-associated illnesses.
Management of chronic cough in select cases under medical supervision.
Pediatric cough suppression in children aged 4 years and older.
Used in formulations appropriate for diabetic patients (sugar-free varieties available).
Short-term symptomatic control of cough where suppressing reflex improves quality of life.
Available as extended-release to provide 12-hour cough relief.

Side Or Adverse Effects

Dizziness and lightheadedness.
Nervousness, anxiety, and restlessness.
Confusion and hallucinations at higher doses or overdose.
Nausea and vomiting.
Drowsiness or sedation in some patients.
Allergic reactions including hives and swelling of face or throat.
Seizures or convulsions in severe overdose cases.
Respiratory depression and slow shallow breathing in overdose.
Potential for serotonin syndrome when combined with serotonergic drugs.
Gastrointestinal upset including stomach pain.
Dry mouth or throat irritation.
Rare instances of cardiac arrhythmias in overdose situations.
Abuse potential at high doses leading to dissociative effects.
Overdose can result in coma and fatal outcomes.
Mild side effects are generally transient and self-limited.

Precautions

Do not use in children under 4 years old due to risk of fatal respiratory depression.
Use caution in patients with chronic bronchitis or emphysema.
Avoid concomitant use with monoamine oxidase inhibitors or within 14 days of MAOI therapy.
Consult healthcare provider before use in pregnancy or breastfeeding.
Avoid alcohol due to increased CNS depression risk.
Do not exceed recommended dosage to prevent toxicity.
Careful use advised in patients with hepatic impairment due to metabolism via liver enzymes.
Patients should avoid driving or operating machinery until response to drug is known.
Check other medications for dextromethorphan content to prevent accidental overdose.
Be alert for signs of serotonin syndrome when combined with antidepressants.
Measure liquid doses accurately using appropriate devices.
Inform surgeons of recent dextromethorphan use before anesthesia or surgery.
Artificially sweetened formulations may contain phenylalanine, relevant for patients with PKU.
Supervise use in elderly patients due to increased susceptibility to side effects.
Seek medical advice if cough persists beyond 7 days or is accompanied by fever or rash.

Warnings

Risk of life-threatening side effects if combined with MAO inhibitors within 14 days.
Death reported in young children from misuse or overdose of cough preparations containing dextromethorphan.
Potential for severe CNS depression and respiratory failure in overdose.
Do not use with other cough/cold/allergy products containing dextromethorphan to avoid overdose.
Avoid use if patient has a known allergy to dextromethorphan or related compounds.
Warning against use in cough caused by smoking, asthma, or emphysema, as ineffective and potentially harmful.
Risk of serotonin syndrome when combined with serotonergic drugs.
Use with caution in patients with history of substance abuse.
Potential for misuse and recreational abuse leading to psychotropic effects.
Be aware of symptoms of allergic reactions requiring immediate medical attention.
Overdose can cause seizures, hallucinations, and coma with fatal risk.
Do not exceed recommended doses; high doses increase adverse reaction risk.
Caution advised in patients with cardiac conditions due to arrhythmia risk in overdose.
Children and elderly patients require careful dosing and monitoring.
Promptly discontinue use if serious neurological or respiratory symptoms appear.

Contraindication

Known hypersensitivity to dextromethorphan or formulation components.
Use within 14 days of treatment with monoamine oxidase inhibitors (MAOIs).
Children less than 4 years of age.
Patients with history of hypersensitivity reactions to similar antitussive agents.
Concomitant use with other medications containing dextromethorphan to prevent overdose.
Use in patients with respiratory depression or impaired breathing reflexes without medical supervision.
Severe hepatic impairment without close monitoring.
Patients with conditions predisposing to serotonin syndrome without medical guidance.
Contraindicated in patients known to have phenylketonuria if using phenylalanine-containing formulations.
Individuals with severe CNS depression or coma.
Known or suspected overdose situations.
Chronic cough due to asthma or emphysema where suppression would be detrimental.
Use in combination with certain serotonergic or sympathomimetic agents without physician approval.
Use in patients with history of seizure disorders unless monitored.
Patients allergic to any excipient in the specific formulation being administered.

Drug Interactions

Monoamine oxidase inhibitors (e.g., isocarboxazid, phenelzine) – risk of hypertensive crises and serotonin syndrome.
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, paroxetine, sertraline – increased risk of serotonin syndrome.
Tricyclic antidepressants (e.g., amitriptyline, imipramine) – enhanced serotonergic effects and potential toxicity.
Ritonavir and other CYP450 inhibitors – can increase plasma levels leading to toxicity.
Quinidine – inhibits CYP2D6 and raises dextromethorphan blood concentrations.
Terbinafine – may affect metabolism leading to increased dextromethorphan effects.
Antihypertensive medications – possible additive CNS depressant effects.
Drugs affecting CYP2D6 enzyme activity may alter dextromethorphan metabolism and effect.
Sibutramine – risk of serotonergic toxicity when combined.
Stimulants such as caffeine and ADHD medications – combined side effects like nervousness and elevated heart rate.
Celecoxib and cinacalcet – potential pharmacodynamic interactions requiring monitoring.
Darifenacin and imatinib – potential pharmacokinetic interactions.
Other over-the-counter cough, cold and allergy medications containing dextromethorphan – risk of inadvertent overdose.
Alcohol – increases CNS depressive effects and risk of sedation.
Diet pills and other stimulants – may exacerbate adverse neurological effects.

Preparations Of The Drug

Immediate-release oral syrup and liquid formulations.
Extended-release oral suspension (e.g., Delsym 12 Hour).
Oral capsules and liquidgels.
Lozenges designed to dissolve slowly in the mouth.
Disintegrating thin strips placed on the tongue.
Combination products with other cough and cold ingredients such as guaifenesin, acetaminophen, and decongestants.
Sugar-free and diabetic-friendly syrup formulations.
Over-the-counter single-ingredient preparations and multicomponent cold remedies.
Pediatric formulations with appropriate dosing and flavoring for children above 4 years.
Phenylalanine-containing formulations for non-PKU patients.
Alcohol-free liquid preparations for sensitive populations.
Liquid formulations with artificial sweeteners and flavor enhancers.
Extended-release formulations designed for twice-daily dosing.
Strip formulations for quicker onset via buccal absorption.
Solid dosage forms suitable for patients with swallowing difficulties.